Visual outcomes and predictors in optic pathway glioma: a single centre study

[1]  Jo-Fen Liu,et al.  NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat , 2020, Neuro-oncology.

[2]  Dorothy A. Thompson,et al.  VEP estimation of visual acuity: a systematic review , 2020, Documenta Ophthalmologica.

[3]  Victor M. Lu,et al.  Efficacy and safety of bevacizumab in progressive pediatric low-grade glioma: a systematic review and meta-analysis of outcome rates. , 2020, Neuro-Oncology Practice.

[4]  B. Geoerger,et al.  Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study , 2019, Clinical Cancer Research.

[5]  David T. W. Jones,et al.  Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. , 2019, The Lancet. Oncology.

[6]  E. De Carli,et al.  Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy—Analysis of a French pediatric historical cohort , 2019, PloS one.

[7]  L. Coleman,et al.  Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low‐grade glioma , 2018, Cancer medicine.

[8]  S. Picton,et al.  Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort , 2018, British Journal of Ophthalmology.

[9]  Michael Bach,et al.  ISCEV standard for clinical visual evoked potentials: (2016 update) , 2016, Documenta Ophthalmologica.

[10]  D. Gutmann,et al.  The molecular and cell biology of pediatric low-grade gliomas , 2014, Oncogene.

[11]  A. Cnaan,et al.  Ganglion cell layer-inner plexiform layer thickness and vision loss in young children with optic pathway gliomas. , 2014, Investigative ophthalmology & visual science.

[12]  N. Freemantle,et al.  Ophthalmic statistics note 1: unit of analysis , 2013, British Journal of Ophthalmology.

[13]  E. Trevisson,et al.  Optical coherence tomography in the diagnosis of optic pathway gliomas. , 2013, Investigative ophthalmology & visual science.

[14]  T. Tihan,et al.  Optic pathway gliomas: a review. , 2013, CNS oncology.

[15]  Yuquan Wen,et al.  Normative reference ranges for the retinal nerve fiber layer, macula, and retinal layer thicknesses in children. , 2013, American journal of ophthalmology.

[16]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[17]  Uri Tabori,et al.  Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. , 2012, Neuro-oncology.

[18]  G. Quinn,et al.  Retinal nerve fiber layer thickness in children with optic pathway gliomas. , 2011, American journal of ophthalmology.

[19]  G. Quinn,et al.  Retinal nerve fiber layer thickness in children with optic pathway gliomas. , 2011, American journal of ophthalmology.

[20]  G. Perilongo,et al.  Optic pathway glioma: Long‐term visual outcome in children without neurofibromatosis type‐1 , 2010, Pediatric blood & cancer.

[21]  S. Zacharoulis,et al.  Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. , 2010, European journal of cancer.

[22]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[23]  C. Westall,et al.  Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials. , 2007, Investigative ophthalmology & visual science.

[24]  D. Gutmann,et al.  Optic pathway gliomas in neurofibromatosis‐1: Controversies and recommendations , 2007, Annals of neurology.

[25]  S. Plon,et al.  Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1 , 2004, American journal of medical genetics. Part A.

[26]  M. Brodsky,et al.  Optic radiation involvement in optic pathway gliomas in neurofibromatosis. , 2004, American journal of ophthalmology.

[27]  R. Schwartz,et al.  Optic Pathway Gliomas in Children With and Without Neurofibromatosis 1 , 2003, Journal of child neurology.

[28]  N. Miller,et al.  Long-term outcome in children with gliomas of the anterior visual pathway. , 2003, Pediatric neurology.

[29]  J. Friedman.  Epidemiology of neurofibromatosis type 1. , 1999, American journal of medical genetics.

[30]  J. Finlay,et al.  Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. , 1997, Journal of neurosurgery.

[31]  D. Louis,et al.  Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the nf1 optic pathway glioma task force , 1997 .

[32]  D. R. Gulati,et al.  Optic pathway gliomas. , 1974, Neurology India.

[33]  T. Kearns,et al.  Gliomas of the optic nerves. , 1958, A.M.A. archives of neurology and psychiatry.

[34]  Jill S Barnholtz-Sloan,et al.  Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. , 2015, Neuro-oncology.

[35]  R. Packer,et al.  Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. , 2014, JAMA ophthalmology.

[36]  R. Avery,et al.  Vision specific quality of life in children with optic pathway gliomas , 2013, Journal of Neuro-Oncology.